• CN
    News & Events

    News & Events

    Chipscreen Highlights: Stay Updated on Recent Hot Topics

    Select year

    2026 2025 2024 2023 2022 Earlier
    shown/page
    15
    5 10 15 20

    2026.07.17

    ThalassaX Therapeutics Announces First Patient Dosed in U.S. Phase I Trial of CS231295, a Brain-Penetrant Aurora B Kinase Selective Inhibitor
    ThalassaX Therapeutics Announces First Patient Dosed in U.S. Phase I Trial of CS231295, a Brain-Penetrant Aurora B Kinase Selective Inhibitor

    Full text

    2026.07.15

    Chipscreen Biosciences' Partner HUYABIO Announces Positive Topline Data from Global Multicenter Phase III Trial of Chidamide (Epidaza®) in Melanoma
    Chipscreen Biosciences' Partner HUYABIO Announces Positive Topline Data from Global Multicenter Phase III Trial of Chidamide (Epidaza®) in Melanoma

    Full text

    2026.06.12

    Chipscreen Biosciences Attends the 2026 SAPA Healthcare Investment Forum, Engaging with the Global Innovation Ecosystem
    Chipscreen Biosciences Attends the 2026 SAPA Healthcare Investment Forum, Engaging with the Global Innovation Ecosystem

    Full text

    2026.05.25

    From Glycemic Control to Addressing Metabolic Root Causes: “White Paper on the Current Status and Future of Comprehensive Insulin Resistance Management in China (2025)” Officially Released
    From Glycemic Control to Addressing Metabolic Root Causes: “White Paper on the Current Status and Future of Comprehensive Insulin Resistance Management in China (2025)” Officially Released

    Full text

    2026.05.14

    Two First-in-Class Drugs from Chipscreen Biosciences Enter the Macao Market, Expanding Patient Access
    Two First-in-Class Drugs from Chipscreen Biosciences Enter the Macao Market, Expanding Patient Access

    Full text

    2026.04.23

    2026 ASCO丨Multiple innovative Drug Studies from Chipscreen Biosciences Selected
    2026 ASCO丨Multiple innovative Drug Studies from Chipscreen Biosciences Selected

    Full text

    2026.04.23

    Published in JAMA ! Chidamide DEB Study Reshapes the First-Line Treatment Landscape for DE-DLBCL
    Published in JAMA ! Chidamide DEB Study Reshapes the First-Line Treatment Landscape for DE-DLBCL

    Full text

    2026.04.18

    AACR 2026 | Dual Breakthroughs in Novel Target ADCs and Small Molecules: Four Original Oncology Pipeline Studies from Chipscreen and Chipscreen Newway Biosciences Accepted for Presentation
    AACR 2026 | Dual Breakthroughs in Novel Target ADCs and Small Molecules: Four Original Oncology Pipeline Studies from Chipscreen and Chipscreen Newway Biosciences Accepted for Presentation

    Full text

    2026.03.16

    First-in-Class Combination Therapy: Clinical Trial Application for Chiglitazar Sodium/Metformin Extended-Release Tablets for Type 2 Diabetes Approved
    First-in-Class Combination Therapy: Clinical Trial Application for Chiglitazar Sodium/Metformin Extended-Release Tablets for Type 2 Diabetes Approved

    Full text

    2026.03.16

    Chipscreen Biosciences Receives NMPA Approval for IND of Novel PRMT5 Inhibitor CS08399 for MTAP-Deficient Tumors
    Chipscreen Biosciences Receives NMPA Approval for IND of Novel PRMT5 Inhibitor CS08399 for MTAP-Deficient Tumors

    Full text

    2025.12.07

    Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug
    Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug

    Full text

    2025.12.05

    Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award
    Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award

    Full text

    2025.11.19

    Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery
    Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery

    Full text

    2025.11.15

    Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF
    Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF

    Full text

    2025.11.03

    ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%
    ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%

    Full text
    Media contact

    Media contact

    • Media contact

      （+86）0755-36993500

    • Media contact

      pr@juliucq.com